Atea Pharmaceuticals (AVIR) Total Current Liabilities (2019 - 2026)

Atea Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $33.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 53.43% year-over-year to $33.4 million; the TTM figure through Mar 2026 stood at $33.4 million (up 53.43% YoY), while the FY2025 annual figure was $39.8 million, up 113.86% from the prior year.
• Total Current Liabilities was $33.4 million for Q1 2026 at Atea Pharmaceuticals, down from $39.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $41.3 million in Q1 2024 to a low of $12.4 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $24.4 million across 5 years, with a median of $21.7 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities tumbled 94.03% in 2022, then soared 234.2% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $18.5 million in 2022, then jumped by 75.21% to $32.4 million in 2023, then tumbled by 42.54% to $18.6 million in 2024, then jumped by 113.86% to $39.8 million in 2025, then dropped by 16.13% to $33.4 million in 2026.
• The last three Total Current Liabilities figures came in at $33.4 million (Q1 2026), $39.8 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.